CA2721007C - Derivatives of galantamine as pro-drugs for the treatment of human brain diseases - Google Patents

Derivatives of galantamine as pro-drugs for the treatment of human brain diseases Download PDF

Info

Publication number
CA2721007C
CA2721007C CA2721007A CA2721007A CA2721007C CA 2721007 C CA2721007 C CA 2721007C CA 2721007 A CA2721007 A CA 2721007A CA 2721007 A CA2721007 A CA 2721007A CA 2721007 C CA2721007 C CA 2721007C
Authority
CA
Canada
Prior art keywords
galantamine
brain
disease
pro
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2721007A
Other languages
English (en)
French (fr)
Other versions
CA2721007A1 (en
Inventor
Alfred Maelicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurodyn Life Sciences Inc
Original Assignee
Neurodyn Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2721007(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurodyn Life Sciences Inc filed Critical Neurodyn Life Sciences Inc
Publication of CA2721007A1 publication Critical patent/CA2721007A1/en
Application granted granted Critical
Publication of CA2721007C publication Critical patent/CA2721007C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2721007A 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases Active CA2721007C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/002929 WO2009127218A1 (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Publications (2)

Publication Number Publication Date
CA2721007A1 CA2721007A1 (en) 2009-10-22
CA2721007C true CA2721007C (en) 2014-04-29

Family

ID=40019199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2721007A Active CA2721007C (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Country Status (8)

Country Link
EP (1) EP2137192B8 (https=)
JP (1) JP5504253B2 (https=)
CN (1) CN102007129B (https=)
CA (1) CA2721007C (https=)
DK (1) DK2137192T3 (https=)
ES (1) ES2463715T3 (https=)
PL (1) PL2137192T3 (https=)
WO (1) WO2009127218A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880399T3 (es) 2012-07-27 2021-11-24 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
ES2700473T3 (es) * 2012-07-27 2019-02-18 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
CA2944017C (en) * 2014-03-25 2022-08-09 Emicipi Llc Treatment of rett syndrome
EP3122363B1 (en) * 2014-03-25 2021-06-23 Synaptec Development LLC Galantamine carbamates for the treatment of autism
AU2015258814B2 (en) * 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
EP4186509A1 (en) 2021-11-26 2023-05-31 Alpha Cognition Inc. Alpha-1062 for treating traumatic brain injury
US12208167B1 (en) * 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine
US12551491B1 (en) * 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0363415B1 (en) 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1282099A (en) 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
WO2000032199A1 (de) 1998-12-01 2000-06-08 Sanochemia Pharmazeutika Aktiengesellschaft Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden
EP2311463A1 (en) 1999-12-10 2011-04-20 Bonnie M. Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
ATE263171T1 (de) 2000-03-31 2004-04-15 Sanochemia Pharmazeutika Ag Neue derivate und analoga von galanthamin
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CA2540248C (en) 2003-09-26 2010-12-07 Scinopharm Taiwan, Ltd. Resolution of a narwedine amide derivative
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Also Published As

Publication number Publication date
DK2137192T3 (da) 2014-05-26
EP2137192B8 (en) 2014-06-11
CN102007129B (zh) 2014-05-07
ES2463715T3 (es) 2014-05-29
WO2009127218A1 (en) 2009-10-22
JP2011516588A (ja) 2011-05-26
JP5504253B2 (ja) 2014-05-28
EP2137192B1 (en) 2014-02-19
CN102007129A (zh) 2011-04-06
EP2137192A1 (en) 2009-12-30
PL2137192T3 (pl) 2014-07-31
CA2721007A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
CA2721007C (en) Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
US10265325B2 (en) Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
CA2696705C (fr) Nouveaux derives de benzothiadiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
de los Rı́os et al. Novel tacrine derivatives that block neuronal calcium channels
ES2274020T3 (es) Derivados de camptotecinas nitrogenadas.
Shurpik et al. Supramolecular neuromuscular blocker inhibition by a pillar [5] arene through aqueous inclusion of rocuronium bromide
CN101289482A (zh) 藤黄酸苷衍生物和类似物及其制备方法和用途
CN104395303B (zh) 苯并间二氧杂环戊烯衍生物及其制备方法和用途
He et al. Synthesis and biological evaluation of bis and monocarbonate prodrugs of 10-hydroxycamptothecins
Boudebbous et al. Synthesis, in vitro and in silico studies of naphto-1, 3-oxazin-3 (2H)-one derivatives as promising inhibitors of cholinesterase and α-glucosidase
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
Reddy et al. Chemical investigation of Mycale mytilorum and a study on toxicity and antidiabetic activity of 5-octadecylpyrrole-2-carboxaldehyde
EP2444121A1 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2015149656A1 (zh) 一类2,2'-串联双噻唑类化合物及其制备方法和用途
WO2005049619A1 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
Kostyuk et al. Electrophilic substitution as a convenient approach to functionalized N-benzyl-1, 4-dihydropyridines
Fatima et al. Synthesis, characterization and biological screening of N-substituted (5-chloro-2-methoxyphenyl) benzene sulfonamide
CN117384167B (zh) 二氢嘧啶[4,5-d]嘧啶-2(H)-酮类Nrf2激活剂及其制备方法与用途
CN104844471A (zh) 一种作为dor受体拮抗剂的化合物
CN103980148A (zh) 硬脂酰氨基酸盐及其制备方法和应用
Soundarrajan et al. Piperidone synthesis using amino acid: A promising scope for green chemistry
ES2310211T3 (es) Derivados de acido 5,6,6a,11b-tetrahidro-7-oxa-5-aza-benzo(c)fluoren-6-carboxilico sustituidos como antagonistas de nmda.
WO2018213258A1 (en) Treatment of merlin-deficient tumors using nae inhibitors
Alaqeel et al. Highly functionalized dispiropyrrolidine embedded indandione hybrids as potent cholinesterase inhibitors
Gallagher Development of alkaloid derivatives to probe novel α4β2 nicotinic acetylcholine receptor (nAChR) binding sites

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407